1007-3418
2013 Issue 7
Critical flicker frequency for the diagnosis of minimal hepatic encephalopathy
wang yue ; shi xiu jiang ; xi er na yi a bu du hei li li ; fan xiao tang ; ma hai lin ; feng juan ; sun jian ; a li ya ; he fang ping
wang yue ; shi xiu jiang ; xi er na yi a bu du hei li li ; fan xiao tang ; ma hai lin ; feng juan ; sun jian ; a li ya ; he fang ping
..............page:546-547
Reactivation of hedgehog signaling pathway is common characteristics of pathogenesis of all kinds of chronic liver diseases
HOU Xin-jiang;YU Yan-yan
HOU Xin-jiang;YU Yan-yan
..............page:558-560
Vitamin D-binding protein as a marker of therapeutic effect in patients with chronic severe hepatitis B
CHEN Yi-yi;CHEN Yu
CHEN Yi-yi;CHEN Yu
..............page:543-545
Primary mitochondrial disorders and liver disease
PENG Xiao-rong;XU Hong-mei
PENG Xiao-rong;XU Hong-mei
..............page:551-553
Efficacy and safety of peginterferon alfa-2a (40 kd) plus adefovir for 96 weeks in HBeAg-negative chronic hepatitis B patients
cao zhen huan ; ma li na ; liu ya li ; jin zuo ; he zhi min ; lu jun feng ; zhang yong hong ; chen xin yue
cao zhen huan ; ma li na ; liu ya li ; jin zuo ; he zhi min ; lu jun feng ; zhang yong hong ; chen xin yue
..............page:498-501
HBeAg seroconversion achieved by sequential peginterferon alfa-2a therapy in chronic hepatitis B patients with unsatisfactory end point following entecavir treatment
CHEN Xue-fu;CHEN Xiao-ping;MA Xiao-jun;CHEN Wen-li;LUO Xiao-dan;LIAO Jin-yao
CHEN Xue-fu;CHEN Xiao-ping;MA Xiao-jun;CHEN Wen-li;LUO Xiao-dan;LIAO Jin-yao
..............page:502-505
..............page:481-483
Supplemental Fuzhenghuayu capsule therapy for improving liver fibrosis markers in patients with chronic hepatitis B following unsatisfactory outcome of nucleos(t)ide analogue monotherapy
TIAN Yu-ling;ZHU Xiao-yun;YIN Wei-wei;ZANG Zhi-dong;WANG Lei;FU Xi-ling
TIAN Yu-ling;ZHU Xiao-yun;YIN Wei-wei;ZANG Zhi-dong;WANG Lei;FU Xi-ling
..............page:514-518
..............page:后插1-后插4
..............page:494-497
Current understanding of the pathogenic mechanisms of HBsAg and their impact on clinical management of hepatitis B
YU Rui;HOU Jin-lin
YU Rui;HOU Jin-lin
..............page:491-493
Aspartate-ornithine granules in the treatment of nonalcoholic steatohepatitis: a multiple-dose parallel controlled clinical trial
tian li yan ; lu lun gen ; tang cheng zuo ; xie yan ; luo he sheng ; tan shi yun ; pang zhi ; zhang ya li ; gong lan bo
tian li yan ; lu lun gen ; tang cheng zuo ; xie yan ; luo he sheng ; tan shi yun ; pang zhi ; zhang ya li ; gong lan bo
..............page:528-532
Role of chemokine CCL28 in hypoxia-induced migration of hepatocellular carcinoma
ZHOU Ying;ZHANG Bo-heng;YIN Xin;REN Zheng-gang
ZHOU Ying;ZHANG Bo-heng;YIN Xin;REN Zheng-gang
..............page:524-527
Functional analysis of hepatitis B virus immune escape mutants with insertion mutations in the surface antigen
YU De-min;ZHANG Dong-hua;JIANG Jie-hong;CHEN Jia;DENG Lin;ZHANG Xin-xin
YU De-min;ZHANG Dong-hua;JIANG Jie-hong;CHEN Jia;DENG Lin;ZHANG Xin-xin
..............page:510-513
Recent perspectives on Notch signaling in normal liver development and pathogenesis of liver diseases
MA Peng-fei;YU Heng-chao;WANG De-sheng;DOU Ke-feng
MA Peng-fei;YU Heng-chao;WANG De-sheng;DOU Ke-feng
..............page:554-557
Meta-analysis of the efficacy and safety of telaprevir combined with peginterferon alfa plus ribavirin in patients with chronic hepatitis C
YAN Shu-shan;XU Dong-hua;ZHANG Peng-jun;YIN Jie;WANG Ping;WANG Xuan
YAN Shu-shan;XU Dong-hua;ZHANG Peng-jun;YIN Jie;WANG Ping;WANG Xuan
..............page:506-509
Response-guided therapy and withdrawal time of peginterferon α for HBeAg-negative chronic hepatitis B
ZHU Yue-yong;JIANG Jia-ji
ZHU Yue-yong;JIANG Jia-ji
..............page:488-490
Abnormal expression of miR-let-7b in primary biliary cirrhosis and its clinical significance
QIAN Cheng;CHEN Sun-xiao;REN Chuan-lu;ZHONG Ren-qian;QIN Qin;DENG An-mei
QIAN Cheng;CHEN Sun-xiao;REN Chuan-lu;ZHONG Ren-qian;QIN Qin;DENG An-mei
..............page:533-536
Aldosterone antagonist inhibits fibrosis-induced NOX4 protein expression in hepatic cells and tissues of rats
ZHANG Wen-yong;LI Yang;LI Ting;NING Zuo-wei;LI Wei;LI Xu
ZHANG Wen-yong;LI Yang;LI Ting;NING Zuo-wei;LI Wei;LI Xu
..............page:519-523
Expression and significance of IL-6 in hepatocellular carcinoma cell lines
HUANG Ling;WEI Ying;CHEN Long;ZOU Can;ZHANG You-shun;YUAN Fang-jun
HUANG Ling;WEI Ying;CHEN Long;ZOU Can;ZHANG You-shun;YUAN Fang-jun
..............page:548-550
Designing efficacious treatment strategies to achieve sustained immunological control of hepatitis infection in HBeAg-positive patients
CHEN Xin-yue;CAO Zhen-huan
CHEN Xin-yue;CAO Zhen-huan
..............page:484-487
Non-canonical Wnt signaling contributes to development of non-alcoholic steatohepatitis in a rat model of type 2 diabetes mellitus
TIAN Feng;ZHANG Ya-jie;WANG Lin
TIAN Feng;ZHANG Ya-jie;WANG Lin
..............page:537-542